Latest developments in gene transfer technology: Achievements, perspectives, and controversies over therapeutic applications

Stem Cells

Volumn 18, Issue 1, 2000, Pages 19-39

  Romano, Gaetano ^a   Micheli, Pietro ^b   Pacilio, Carmen ^c   Giordano, Antonio ^c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b AO Dei Colli Hospital for Infectious Diseases D Cotugno   (Italy)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Clinical trials; Ex vivo gene transfer; Gene therapy; Genetic immunization; In vivo gene delivery systems

Indexed keywords

VIRUS VECTOR;

GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC DISORDER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; REVIEW; TREATMENT INDICATION; VIRUS TRANSMISSION;

EBOLA VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; INFLUENZA VIRUS; LA CROSSE VIRUS;

EID: 0033974016     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.18-1-19     Document Type: Review

References (272)

1. Blaese RM, Culver KW, Miller AD et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 1995;270:475-480.
2. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997;89:21-39.
3. Pilaro AM, Serabian MA. Preclinical development strategies for novel gene therapeutic products. Toxicol Pathol 1999;27:4-7.
4. Regulatory issues. Gene therapy advisory committe. Report on the potential use of gene therapy in utero. Hum Gene Ther 1999;10:689-692.
5. Romano G, Pacilio C, Giordano A. Gene transfer technology in therapy: current applications and future goals. STEM CELLS 1999;17:191-202.
6. Rowe PM. Gene therapy: a long way to go, but moving fast. Lancet 1999;353:2133.
7. Hollingsworth SJ, Barker SGE. Gene therapy: into the future of surgery. Lancet 1999;353(suppl 1):SL19-SL20.
8. Fishman RHB. Gene therapy takes further steps into the clinic. Lancet 1999;353:848.
9. Husten L. Gene therapy door opened wider. Lancet 1998;352:1603.
10. Gene therapy for rare diseases. (Editorial). Nat Genet 1999;22:313-314.
11. von der Leyen HE, Braun-Dullaeus R, Mann MJ et al. A pressure-mediated nonviral method for efficient arterial gene and oligonucleotide transfer. Hum Gene Ther 1999;10:2355-2364.
12. Imaoka T, Date I, Ohmoto T et al. Significant behavioral recovery in Parkinson's disease model by direct intracerebral gene transfer using continuous injection of a plasmid DNA-liposome complex. Hum Gene Ther 1998;9:1093-1102.
13. Ross CJD, Ralph M, Chang PL. Delivery of recombinant gene products to the central nervous system with nonautologous cells in alginate microcapsules. Hum Gene Ther 1999;10:49-59.
14. Ridet J-L, Corti O, Pencavlet P et al. Toward autologous ex vivo gene therapy for the central nervous system with human adult astrocytes. Hum Gene Ther 1999;10:271-280.
15. Alden TD, Pittman DD, Hankins GR et al. In vivo endochondrial bone formation using a bone morphogenetic protein 2 adenoviral vector. Hum Gene Ther 1999;10:2245-2253.
16. Shiotani A, O'Malley BW Jr, Coleman ME et al. Reinnervation of motor endplates and increased muscle fiber size after human insulin-like growth factor I gene transfer into the paralyzed larynx. Hum Gene Ther 1998;9:2039-2047.
17. Bonadio J, Smiley E, Patil P et al. Localized, direct plasmid gene delivery in vivo: prolonged therapy results in reproducible tissue regeneration. Nat Med 1999;5:753-759.
18. Roy K, Mao H-Q, Huang S-K et al. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 1999;5:387-391.
19. Esakof DD, Maysky M, Losordo DW et al. Intraoperative multiplane transesophageal echocardiography for guiding direct myocardial gene transfer of vascular endothelial growth factor in patients with refractory angina pectoris. Hum Gene Ther 1999;10:2307-2314.
20. 165 as sole therapy for myocardial ischemia. Circulation 1998;98:2800-2804.
21. 165 following intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998;97:1114-1123.
22. Haynes BF. HIV vaccines: where we are and where we are going. Lancet 1996;348:933-937.
23. Weber J. Distinguishing between response to HIV vaccine and response to HIV. Lancet 1996;350:230-231.
24. Romano G, Massi D, Giordano A. The standpoint of AIDS research and therapy programs. Anticancer Res 1998;18:2763-2778.
25. Boyer J, Ugen K, Wang B et al. Protection of chimpanzees from high dose heterologous challenge by DNA vaccination. Nat Med 1997;3:526-532.
26. Tascon RC, Colston MJ, Ragno S et al. Vaccination against tuberculosis by DNA injection. Nat Med 1996;2:888-892.
27. Ulmer JB, Donnelly JJ, Parker SE et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993;259:1745-1749.
28. Raz E, Carson DA, Parker SE et al. Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci USA 1994;91:9519-9523.
29. - interferon gamma-, and nitric oxide-dependent immunity. J Exp Med 1996;183:1739-1746.
30. Sedegah M, Hedstrom R, Hobart P et al. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci USA 1994;91:9866-9870.
31. Xu L, Sanchez A, Yang Z-Y et al. Immunization for Ebola infection. Nat Med 1998;4:37-42.
32. Seder RA, Gurunathan S. DNA vaccines - designer vaccines for the 21st century. N Engl J Med 1999;341:277-278.
33. Romano G, Kasten M, Giordano A. Current understanding of AIDS pathogenesis. Anticancer Res (in press).
34. Cairns JS, Sarver N. New vectors for HIV vaccine delivery. AIDS Res Hum Retroviruses 1998;14:1501-1508.
35. Ugen KE, Nyland SB, Boyer JD et al. DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans. Vaccine 1998;16:1818-1821.
36. Parker SE, Borellini F, Wenk ML et al. Plasmid DNA malaria vaccine: tissue distribution and safety studies in mice and rabbits. Hum Gene Ther 1999;10:741-758.
37. Wang R, Doolan DL, Le TP et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998;282:476-480.
38. Andre FE. Approaches to a vaccine against hepatitis A: development and manufacture of an inactivated vaccine. J Infect Dis 1995:171 (suppl 1):S33-S39.
39. McCluskie MJ, Brazolot Millan CL, Gramziniski RA et al. Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. Mol Med 1999;5:287-300.
40. Sallberg M, Hughes J, Javadian A et al. Genetic immunization of chimpanzees chronically infected with the hepatitis B virus, using a recombinant retroviral vector encoding the hepatitis B virus core antigen. Hum Gene Ther 1998;9:1719-1729.
41. Geissler M, Schirmberck R, Reimann J et al. Cytokine and hepatitis B virus DNA co-immunizations enhance cellular and humoral immune responses to the middle but not to the large hepatitis B virus surface antigen in mice. Hepatology 1998;28:202-210.
42. + cellular responses after genetic immunization with retroviral vectors expressing different forms of the hepatitis B virus core and e antigens. J Virol 1997;71:5295-5303.
43. Forns X, Emerson SU, Tobin GJ et al. DNA immunization of mice and macaques with plasmids encoding hepatitis C virus envelope E2 protein expressed intracellularly and on the cell surface. Vaccine 1999;17:1992-2002.
44. Saito T, Sherman GJ, Kurokohchi K et al. Plasmid DNA-based immunization for hepatitis C virus structural proteins: immune responses in mice. Gastroenterology 1997;112:1410-1414.
45. Inchauspe G, Vitviski L, Major ME et al. Plasmid DNA expressing a secreted or a nonsecreted form of hepatitis C virus nucleocapsid: comparative studies of antibody and T-helper responses following genetic immunization. DNA Cell Biol 1997;16:185-195.
46. + T cells. Hum Gene Ther 1999;10:1649-1658.
47. Lu L, Lee WC, Takayama T et al. Genetic engineering of dendritic cells to express immunosuppressive molecules. J Leukoc Biol 1999;66:293-296.
48. Gallichan WS, Kafri T, Krahl T et al. Lentivirus-mediated transduction of islet grafts with interleukin 4 results in sustained gene expression and protection from insulitis. Hum Gene Ther 1998;9:2717-2726.
49. Chen W, Bennett CF, Wang M-E et al. Perfusion of kidneys with unformulated "naked" intercellular adhesion molecule-1 antisense oligodeoxynucleotides prevents ischemic/reperfusion injury. Transplantation 1999;68:880-887.
50. Posten RS. Mann MJ, Hoyt EG et al. Antisense oligodeoxynucleotides prevent acute cardiac allograft rejection via a novel, nontoxic, highly efficient transfection method. Transplantation 1999;68:825-832.
51. Billings PR. In utero gene therapy. The case against. Nat Med 1999;5:255-256.
52. Schneider H, Coutelle C. In utero gene therapy. The case for. Nat Med 1999;5:256-257.
53. Billings PR, Hubbard R, Newman SA. Human germline gene modification: a dissent. Lancet 1999;353:1873-1875.
54. Riddell SR, Elliott M, Lewinsohn DA et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 1996;2:216-223.
55. Vrancken Peeters MJ, Perkins AL, Kay MA. Method for multiple portal vein infusions in mice: quantitation of adenovirus-mediated hepatic gene transfer. Biotechniques 1996;20:278-285.
56. Ye X, Gao GP, Pabin C et al. Evaluating the potential of germ line transmission after intravenous administration of recombinant adenovirus in the C3H mouse. Hum Gene Ther 1998;9:2135-2142.
57. Hofmann A, Nolan GP, Blau HM. Rapid retroviral delivery of tetracycline-inducible genes in a single autoregulatory cassette. Proc Natl Acad Sci USA 1996;93:5185-5190.
58. Paulus W, Baur I, Boyce FM et al. Self-contained tetracycline-regulated retroviral vector system for gene delivery to mammalian cells. J Virol 1996;70:62-67.
59. Westerman KA, Leboulch P. Reversible immortalization of mammalian cells mediated by retroviral transfer and site-specific recombination. Proc Natl Acad Sci USA 1996;93:8971-8976.
60. Puttaraju M, Jamison SF, Mansfield SG et al. Spliceosome-mediated RNA trans-splicing: a tool for gene therapy. Nat Biotechnol 1999;17:246-252.
61. Berns A. Turning on tumors to study cancer progression. Nat Med 1999;5:989-990.
62. Werstuck G, Green MR. Controlling gene expression in living cells through small molecule-RNA interactions. Science 1998;282:296-298.
63. Bohl D, Naffakh N, Heard JM. Long-term control of erythropoietin secretion by doxycycline in mice transplanted with engineered primary myoblasts. Nat Med 1997;3:278-279.
64. Harding TC, Geddes BJ, Murphy D et al. Switching transgene expression in the brain using an adenoviral tetracycline-regulatable system. Nat Biotechnol 1998;16:553-555.
65. Chin L, Tam A, Pomerantz J et al. Essential role for oncogenic Ras in tumor maintenance. Nature 1999;400:468-472.
66. Ewald D, Li M, Efrat S et al. Time-sensitive reversal of hyperplasia in transgenic mice expressing SV40 T antigen. Science 1996;273:1384-1386.
67. Pelengaris S, Littlewood T, Khan M et al. Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell 1999;3:565-577.
68. Cournoyer D, Caskey CT. Gene therapy of the immune system. Annu Rev Immunol 1993;11:297-329.
69. Gilboa E. Retroviral gene transfer, applications to human gene therapy. Prog Clin Biol Res 1990352:301-311.
70. Kohn DB, Anderson WF, Blaese MB. Gene therapy for genetic diseases. Cancer Invest 1989;7:179-192.
71. Miller AD. Retrovirus packaging cells. Hum Gene Ther 1990;1:5-14.
72. Temin HM. Retrovirus vectors for gene transfer: efficient integration into and expression of exogenous DNA in vertebrate cell genomes. In: Kucherlapati R, ed. Gene Transfer. New York: Plenum Press, 1986:144-187.
73. Ballay A, Levrero M, Buendia MA et al. In vitro and in vivo synthesis of the hepatitis B virus surface antigen and of the receptor for polymerized human serum albumin from recombinant human adenoviruses. EMBO J 1985;4:3861-3865.
74. Karlsson S, Van Doren K, Schweiger SG et al. Stable gene transfer and tissue-specific expression of a human globin gene using adenoviral vectors. EMBO J 1985;5:2377-2385.
75. Yamada M, Lewis JA, Grodzicker T. Overproduction of the protein product of a nonselected foreign gene carried by an adenovirus vector. Proc Natl Acad Sci USA 1985;82:3567-3571.
76. Stratford-Perricaudet LD, Levrero M, Chasse JF et al. Evaluation of the transfer and expression in mice of an enzyme encoding gene using a human adenovirus vector. Hum Gene Ther 1990;1:241-256.
77. Lemarchand P, Jaffe HA, Danel C et al. Adenovirus-mediated transfer of a recombinant human alpha 1-antitrypsin cDNA to human endothelial cells. Proc Natl Acad Sci USA 1992;89:6482-6486.
78. Rosenfeld MA, Yoshimura K, Trapnell BC et al. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 1992;68:143-155.
79. Podsakoff G, Wong KK Jr, Chatterjee S. Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors. J Virol 1994;68:5656-5666.
80. Kotin RM, Berns KI. Organization of adeno-associated virus DNA in latently infected Detroit 6 cells. Virology 1989;170:460-467.
81. Kotin RM, Siniscalco M, Samulski RJ et al. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 1990;87:2211-2215.
82. Kotin RM, Linden RM, Berns KI. Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J 1992;11:5071-5078.
83. Kotin RM, Menninger JC, Ward DC et al. Mapping and direct visualization of a region-specific viral DNA integration site on chromosome 19q13-qter. Genomics 1991;10:831-834.
84. Samulski RJ, Zhu X, Xiao X et al. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J 1991;10:3941-3950.
85. Russell DW, Miller AD, Alexander IE. Adeno-associated virus vectors preferentially transduce cells in S phase. Proc Natl Acad Sci USA 1994;91:8915-8919.
86. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 1996;93:11341-11348.
87. Paoletti E. Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci USA 1996;93:11349-11353.
88. Glorioso JC, De Luca NA, Fink DJ. Development and application of herpes simplex virus vectors for human gene therapy. Annu Rev Microbiol 1995;49:675-710.
89. Thierry AR, Dritschilo A. Intracellular availability of unmodified, phosphorothioated and liposomal encapsulated oligodeoxynucleotides for antisense activity. Nucleic Acids Res 1992;20:5691-5698.
90. Bennet CF, Chiang MY, Chan H et al. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol 1992;41:1023-1033.
91. Ropert C, Malvy C, Couvreur P. Inhibition of the Friend retrovirus by antisense oligonucleotides encapsulated in liposomes: mechanism of action. Pharm Res 1993;10:1427-1433.
92. Thierry AR, Rahman A, Dritschilo A. Overcoming multidrug resistance in human tumor cells using free and liposomally encapsulated antisense oligodeoxynucleotides. Biochem Biophys Res Commun 1993;190:952-960.
93. Ryser HP, Shen WC. Conjugation of methotrexate to poly(L-lysine) increases drug transport and overcomes drug resistance in cultured cells. Proc Natl Acad Sci USA 1978;75:3867-3870.
94. 4-poly(L-lisine) conjugates in intact cells. Biochemistry 1986;25:3730-3736.
95. Russell DW, Miller AD. Foami virus vectors. J Virol 1996;70:217-222.
96. Wu M, Mergia A. Packaging cell lines for simian foamy virus type 1 vectors. J Virol 1999;73:4498-4501.
97. Wu M, Chari S, Yanchis T et al. cis-Acting sequences required for simian foamy virus type 1 vectors. J Virol 1998;72:3451-3455.
98. Naldini L, Blomer U, Gallat P et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996;272:263-267.
99. Naldini L, Blomer U, Gage FH et al. Efficient gene transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996;93:11382-11388.
100. Poeschla E, Corbeau P, Wong-Staal F. Development of HIV vectors for anti-HIV gene therapy. Proc Natl Acad Sci USA 1996;93:11395-11399.
101. Srinivasakumar N, Chazal N, Prasad CH-MS et al. The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines. J Virol 1997;71:5841-5848.
102. Zufferey R, Nagy D, Mandel RJ et al. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997;15:871-875.
103. Kim VN, Mitrophanous K, Kingsman SM et al. Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J Virol 1998;72:811-816.
104. Miyoshi H, Smith KA, Mosier DE et al. Transduction of human CD34+ cells that mediate long-term engraftement of NOD/SCID mice by HIV vectors. Science 1999:283:682-686.
105. Johnston JC, Gasmi M, Lim LE et al. Minimum requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors. J Virol 1999;73:4991-5000.
106. Johnston J, Power C. Productive infection of human peripheral blood mononuclear cells by feline immunodeficiency virus: implications for vector development. J Virol 1999;73:2491-2498.
107. Poeschla EM, Wong-Staal F, Looney DJ. Efficient transduction of nondividing cells by feline immunodeficiency virus lentiviral vectors. Nat Med 1998;4:354-357.
108. 1491aa is replication defective due to a failure in autoregulation. Proc Natl Acad Sci USA 1996;93:11321-11326.
109. Robertson ES, Ooka T, Kieff ED. Epstein-Barr virus vectors for gene delivery to B lymphocytes. Proc Natl Acad Sci USA 1996;93:11334-11340.
110. Palese P, Zheng H, Engelhardt OG et al. Negative-strand RNA viruses: genetic engineering and applications. Proc Natl Acad Sci USA 1996;93:11354-11358.
111. Frolov I, Hoffman TA, Pragai BM et al. Alphavirus-based expression vectors: strategies and applications. Proc Natl Acad Sci USA 1996;93:11371-11377.
112. Duboise SM, Guo J, Desrosiers RC et al. Use of virion DNA as a cloning vector for the construction of mutant and recombinant herpesviruses. Proc Natl Acad Sci USA 1996;93:11389-11394.
113. Feng M, Jackson WH, Goldman CK et al. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector. Nat Biotechnol 1997;15:866-870.
114. Duisit G, Salvetti A, Moullier P et al. Functional characterization of adenoviral/retroviral chimeric vectors and their use for efficient screening of retroviral producer cell lines. Hum Gene Ther 1999;10:189-200.
115. Wahlfors JJ, Morgan RS. Production of minigene-containing retroviral vectors using an alphavirus/retrovirus hybrid vector system. Hum Gene Ther 1999;10:1197-1206.
116. Weiss RA. Retroviral zoonoses. Nat Med 1998;4:391-392.
117. Weiss RA, Wrangham RW. From Pan to pandemic. Nature 1999;397:385-386.
118. Shinnick TM, Lerner RA, Sutcliffe JG. Nucleotide sequence of Moloney murine leukemia virus. Nature 1981;293:543-548.
119. + peripheral blood lymphocytes in HIV discordant identical twins. Hum Gene Ther 1999;10:1401-1421.
120. + hematopoietic progenitor cells transduced with an anti-HIV ribozyme. Hum Gene Ther 1999;10:2255-2270.
121. Morgan RA. Gene therapy for HIV infection. Clin Exp Immunol 1997;107(suppl 1):41-44.
122. Wong-Staal F, Poeschla EM, Looney DJ. A controlled, phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA. Hum Gene Ther 1998;9:2407-2425.
123. + cells from the bone marrow of human immuno-deficiency virus-1-infected children. Blood 1999;94:368-371.
124. + progenitor cells by granulocyte colony-stimulating factor in human immunodeficiency virus type 1-infected adults. Blood 1996;88:3329-3335.
125. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990;10:4239-4242.
126. Bieniasz PD, Weiss RA, McClure MO. Cell cycle dependence of foami retrovirus infection. J Virol 1995;69:7295-7299.
127. Ferry N, Heard JM. Liver-directed gene transfer vectors. Hum Gene Ther 1998;9:1975-1981.
128. Grossman M, Raper SE, Kozarsky K et al. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesteremia. Nat Genet 1994;6:335-341.
129. Grossman M, Rader DJ, Muler DWM et al. A pilot of ex vivo gene therapy for homozygous familial hypercholesterolemia. Nat Med 1995;1:1148-1154.
130. Ganem D. An advance in liver-specific gene delivery. Proc Natl Acad Sci USA 1999;96:11696-11697.
131. Protzer U, Nassal M, Chiang P-W et al. Interferon gene transfer by a hepatitis B virus vector efficiently suppress wild-type virus infection. Proc Natl Acad Sci USA 1999;96:10818-10823.
132. Burns JC, Friedman T, Driever W et al. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian cells. Proc Natl Acad Sci USA 1993;90:8033-8037.
133. Yee J-K, Miyanohara A, LaPorte P et al. A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc Natl Acad Sci USA 1994;91:9564-9568.
134. Takeuchi Y, Cosset FL, Lackmann PJ et al. Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J Virol 1994;68:8001-8007.
135. Wlesh RM, O'Donnell CL, Reed DJ et al. Evaluation of the Galalphal-3Gal epitope as a host modification factor eliciting natural immunity to enveloped viruses. J Virol 1998;72:4650-4656.
136. Takeuchi Y, Liong SH, Bieniasz PD et al. Sensitization of rabdo-, lenti-, and spumaviruses to human serum by galactosyl(alpha1-3) galactosylation. J Virol 1997;71:6178.
137. Batra RK, Olsen JC, Hoganson DK et al. Retroviral gene transfer is inhibited by chondroitin sulfate proteoglycans/glycosaminoglycans in malignant pleural effusions. J Biol Chem 1997;272:11736-11743.
138. Ory DS, Neugeboren BA, Mulligan RC. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci USA 1996;93:11400-11406.
139. Spitzer D, Hauser H, Wirth D. Complement-protected amphotropic retroviruses from murine packaging cells. Hum Gene Ther 1999;10:1893-1902.
140. Pawliuk R, Bachelot T, Wise RJ et al. Long-term cure of the photosensitivity of murine erythropoietic protoporphyria by preselective gene therapy. Nat Med 1999;7:768-773.
141. + T lymphocytes: green fluorescent protein-engineered, encephalitogenic T cells illuminate brain autoimmune responses. Nat Med 1999;5:843-847.
142. Ramiro AR, De Yebenes VG, Trigueros C et al. Enhanced green fluorescent protein as an efficient reporter gene for retroviral transduction of human multipotent lymphoid precursors. Hum Gene Ther 1998;9:1103-1109.
143. Dardalhon V, Noraz N, Pollok K et al. Green fluorescent protein as a selectable marker of fibronectin-facilitated retroviral gene transfer in primary human T lymphocytes. Hum Gene Ther 1999;10:5-14.
144. + cells. Hum Gene Ther 1998;9:1025-1036.
145. Rosenzweig M, MacVittie TJ, Harper D et al. Efficient and durable gene marking of hematopoietic progenitor cells in nonhuman primates after nonablative conditioning. Blood 1999;94:2271-2286.
146. Douer D, Ramezani L, Mohrbacher AF et al. The influence of patient-related factors on ex vivo retroviral-mediated gene transfer into mobilized peripheral myeloid progenitors. Hum Gene Ther 1998;9:1061-1068.
147. Wu AG, Liu X, Mazumder A et al. Improvement of gene transduction efficiency in T lymphocytes using retroviral vectors. Hum Gene Ther 1999;10:977-982.
148. Hanenberg H, Xiac XL, Dilloo D et al. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat Med 1996;2:876-882.
149. Goerner M, Bruno B, McSweeney PA et al. The use of granulocyte colony-stimulating factor during retroviral transduction on fibronectin fragment CH-296 enhance gene transfer into hematopoietic repopulating cells in dogs. Blood 1999;94:2287-2292.
150. Murray L, Luens K, Tushinski R et al. Optimization of retroviral gene transduction of mobilized primitive hematopoietic progenitors by using thrombopoietin, flt3, and kit ligands and RetroNectin culture. Hum Gene Ther 1999;10:1743-1752.
151. - human hematopoietic cells by HIV-1-based lentiviral vectors. Proc Natl Acad Sci USA 1999;96:2988-2993.
152. Sutton RE, Wu HT, Rigg R et al. Human immunodeficiency virus type 1 vectors efficiently transduce human hematopoietic stem cells. J Virol 1998;72:5781-5788.
153. - cell transduction via lentivirus-based gene transfer vectors. Hum Gene Ther 1999;10:1479-1489.
154. Martineau D, Klump WM, McCormack JE et al. Evaluation of PCR and ELISA assays for screening clinical trial subjects for replication-competent retroviruses. Hum Gene Ther 1997;8:1231-1241.
155. Nemunaitis J, Fong T, Burrows F et al. Phase I trial of interferon gamma retroviral vector administrated intratumorally with multiple courses in patients with metastatic melanoma. Hum Gene Ther 1999;10:1289-1298.
156. Pear WS, Nolan GP, Scott ML et al. Production of helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993;90:8392-8396.
157. Serabian MA, Pilaro AM. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond. Toxicol Pathol 1999;27:27-31.
158. Yang S, Delgado R, King SR et al. Generation of retroviral vector for clinical studies using transient transfection. Hum Gene Ther 1999;10:123-132.
159. Santti J, Hyypia T, Kinnunen L et al. Evidence of recombination among enteroviruses. J Virol 1999;73:8741-8749.
160. Johnson WE, Coffin JM. Constructing primate phylogenies from ancient retrovirus sequences. Proc Natl Acad Sci USA 1999;96:10254-10260.
161. Larsson E, Anderson G. Beneficial role of human endogenous retroviruses: facts and hypothesis. Scand J Immunol 1998;48:329-338.
162. Lower R, Boller K, Hasenmaier B et al. Identification of human endogenous retroviruses with complex mRNA expression and particle formation. Proc Natl Acad Sci USA 1993;90:4480-4484.
163. Best S, Le Tissier PR, Stoye JP. Endogenous retroviruses and the evolution of resistance to retroviral infection. Trends Microbiol 1997;5:313-318.
164. Conrad B, Weissmahr RN, Boni J et al. A human endogenous retroviral superantigen as candidate autoimmune gene in type I diabetes. Cell 1997;90:303-313.
165. Perron H, Geny C, Laurent A et al. Leptomeningeal cell line from multiple sclerosis with reverse transcriptase activity and viral particles. Res Virol 1989;140:551-561.
166. Perron H, Lalande B, Gratacap B et al. Isolation of a retrovirus from patients with multiple sclerosis. Lancet 1991;337:862-863.
167. Blond J-L, Beseme F, Duret L et al. Molecular characterization and placental expression of HERV-W, a new human endogenous retrovirus family. J Virol 1999;73:1175-1185.
168. Connelly S, Smith G, Dhir G et al. In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice. Hum Gene Ther 1995;6:185-193.
169. Barr D, Tubb J, Fergusson D et al. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther 1995;2:151-155.
170. Dai Y, Schwarz EM, Gu D et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 1995;92:1401-1405.
171. Chan SY, Kewang L, Piccotti JR et al. Tissue-specific consequences of the anti-adenoviral immune response: implications for cadiac transplants. Nat Med 1999;5:1143-1149.
172. Gautsch JW, Wilson MC. Delayed de novo methylation in teratocarcinoma suggests additional tissue-specific mechanisms for controlling gene expression. Nature 1983;301:32-37.
173. Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1986;321:209-213.
174. Lund AH, Duch M, Pedersen FS. Transcriptional silencing of retroviral vectors. J Biomed Sci 1996;3:365-378.
175. Macleod D, Charlton J, Mullins J et al. Sp1 sites in the mouse aprt gene promoter are required to prevent methylation of the CpG island. Genes Dev 1994;2282-2292.
176. Grez M, Zorning M, Nowock J et al. A single point mutation activates the Moloney murine leukemia virus long terminal repeat in embryonal stem cells, J Virol 1991;65:4691-4698.
177. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. Biotechniques 1989;7:980-990.
178. Hawley RG, Lieu FHL, Fong AZC et al. Versatile retroviral vectors for potential use in gene therapy. Gene Ther 1994;1:136-138.
179. Laker C, Meyer J, Schopen A et al. Host cis-mediated extinction of a retrovirus permissive for expression in embryonal stem cells during differentiation. J Virol 72:339-348.
180. Tsukiyama T, Ueda H, Hirose S et al. Embryonal long terminal repeat-binding protein is a murine homolg of FTZ-Fl, a member of the steroid receptor superfamily. Mol Cell Biol 1992;12:1286-1291.
181. Croce CM, Sozzi G, Huebner K. Role of FHIT in human cancer. J Clin Oncol 1999;17:1618-1624.
182. Powell SK, Kaloss M, Burimski I et al. In vitro analysis of transformation potential associated with retroviral vector insertions. Hum Gene Ther 1999;10:2123-2132.
183. Kakunaga T. A quantitative system for assay of malignant transformation by chemical carcinogens using a clone derived from BALB-3T3. Int J Cancer 1973:12:463-473.
184. Varmus HE, Quintrell N, Ortiz S. Retroviruses as mutagens: insertion and excision of a nontransforming provirus alter expression of a resident transforming provirus. Cell 1981;25:23-36.
185. King W, Patel MD, Lobel LI et al. Insertion mutagenesis of embryonal carcinoma cells by retroviruses. Science 1985;228:554-558.
186. Chang WS, Hubbard C, Friedel C et al. Enrichment of insertional mutants following retrovirus gene trap selection. Virology 1993;193:737-747.
187. Dorssers LCJ, Van Agthoven T, Dekker A et al. Induction of anti-estrogen resistance in human breast cancer cells by random insertional mutagenesis using defective retroviruses: identification of bcar-1, a common integration site. Mol Endocrinol 1993;7:870-878.
188. Grosovsky AJ, Skandalis A, Hasegawa L et al. Insertional inactivation of the tk locus in a human B lymphoblastoid cell line by a retroviral shuttle vector. Mutat Res 1993;289:297-308.
189. Hubbard SC, Walls L, Ruley HE et al. Generation of Chinese hamster ovary cell glycosylation mutants by retroviral insertional mutagenesis. J Biol Chem 1994;269:3717-3724.
190. von Laer D, Thomsen S, Vogt B et al. Entry of amphotropic and 10A1 pseudotyped murine retroviruses is restricted in hematopoietic stem cells. J Virol 1998;72:1424-1430.
191. Thomsen S, Vogt B, von Laer D et al. Lack of functional Pit-1 and Pit-2 expression on hematopoietic stem cell lines. Acta Haematol 1998;99:148-155.
192. Zhao Y, Zhu L, Lee S et al. Identification of the block in targeted retroviral-mediated gene transfer. Proc Natl Acad Sci USA 1999;96:4005-4010.
193. Nyberg-Hoffman C, Aguilar-Cordova E. Instability of adenoviral vectors during transport and its impication for clinical trials. Nat Med 1999;5:955-957.
194. Zabner J, Couture LA, Gregory RJ et al. Adenovirus-mediated gene transfer transiently corrects the chlorine transport defect in nasal epithelia of patients with CF. Cell 1993;75:207-216.
195. Batshaw ML, Wilson JM, Raper S et al. (Clinical protocol). Recombinant adenovirus gene transfer in adults with partial ornitine transcarbamylase deficiency (OTCD). Hum Gene Ther 1999;10:2419-2437.
196. Jaffe HA, Danel C, Longenecker G et al. Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nat Genet 1992;1:372-378.
197. Prevec L, Schneider M, Rosenthal KL et al. Use of human adenovirus-based vectors for antigen expression in animals. J Gen Virol 1989;70:429-434.
198. Yang Y, Li Q, Ertl HCJ et al. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995;69:2004-2015.
199. Tripathy SK, Black HB, Goldwasser E et al. Immune responses to transgene-encoded proteins limits the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 1996;2:545-550.
200. Yang Y, Joos KU, Su Q et al. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther 1996;3:137-144.
201. + CTLs in vivo. J Immunol 1995;155:2564-2570.
202. DeMatteo RP, Markman JF, Kozarsky KF et al. Prolongation of adenoviral transgene expression in mouse liver by T lymphocyte subset depletion. Gene Ther 1996;3:4-12.
203. Vilquin JT, Guerette B, Kinoshita I et al. FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. Hum Gene Ther 1995;6:1391-1401.
204. Dai Y, Schwarz EM, Gu D et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 1995;92:1401-1405.
205. Engelhardt JF, Yang Y, Stratford-Perricaudet LD et al. Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with E1-deleted adenoviruses. Nat Genet 1993;4:27-34.
206. Graham FL, Smiley J, Russel WC et al. Characteristics of a human cell line transformed by the DNA from human adenovirus 5. J Gen Virol 1977;36:59-72.
207. Bett AJ, Prevec L, Graham FL. Packaging capacity and stability of human adenovirus type 5 vectors. J Virol 1993;67:5911-5921.
208. Sterman DH, Treat J, Litzky LA et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancies: results of a phase I clinical trials in malignant mesothelioma. Hum Gene Ther 1998;9:1083-1092.
209. Herman JR, Adler HL, Aguilard-Cordova E et al. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther 1999;10:1239-1249.
210. Molnar-Kimber KL, Sterman DH, Chang M et al. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum Gene Ther 1998;9:2121-2133.
211. Schreiber S, Kampgen E, Wagner E et al. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study. Hum Gene Ther 1999;10:983-993.
212. Schuller M, Rochlitz C, Horowitz JA et al. A phase I study of adenovirus-mediated wild type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum Gene Ther 1998;9:2075-2082.
213. Habib NA, Hodgson HJF, Lemoine N et al. (Clinical protocol). A phase I/II study of hepatic artery infusion with wtp53-CMV-Ad in metastatic malignant liver tumours. Hum Gene Ther 1999;10:2019-2034.
214. Sterman DH, Kaiser LR, Albelda SM. Gene therapy for malignant pleural mesothelioma. Hematol Oncol Clin North Am 1998;12:553-568.
215. Bruder JT, Jie T, McVey DL et al. Expression of gp19K increases the persistence of transgene expression from an adenovirus vector in the mouse lung and liver. J Virol 1997;71:7623-7628.
216. Ilan Y, Droguett G, Chowdhury NR et al. Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Proc Natl Acad Sci USA 1997;94:2587-2592.
217. Lee MG, Abina MA, Haddada H et al. The constitutive expression of the immunomodulatory gp19k protein in E1-, E3-adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector. Gene Ther 1995;2:256-262.
218. Beier DC, Cox JH, Vining DR et al. Association of human class I MHC alleles with the adenovirus E3/19K protein. J Immunol 1994;152:3862-3872.
219. Engelhardt JF, Ye X, Doranz B et al. Ablation of E2A in recombinant adenovirus improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 1994;91:6196-6200.
220. Ye XH, Robinson MB, Batshaw ML et al. Prolonged metabolic correction in adult ornitine transcarbamylase-deficient mice with adenoviral vectors. J Biol Chem 1996;271:3639-3646.
221. Yang Y, Nunes FA, Berencsi K et al. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet 1994;7:362-369.
222. Yeh P, Dedieu JF, Orsini C et al. Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit. J Virol 1996;70:559-565.
223. Dedieu JF, Vigne E, Torrent C et al. Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. J Virol 1997;71:4626-4637.
224. Wang Q, Greenburg G, Bunch D et al. Persistent transgene expression in mouse liver following in vivo gene transfer with a deltaE1/deltaE4 adenovirus vector. GeneTher 1997;4:393-400.
225. Gao GP, Yang YP, Wilson JM. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol 1996;70:8934-8943.
226. Galderisi U, Cascino A, Giordano A. Antisense oligonucleotides as therapeutic agents. J Cell Physiol 1999;181:251-257.
227. Brough DE, Hsu C, Kulesa VA et al. Activation of transgene expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors in vivo. J Virol 1997;71:9206-9213.
228. Worgall S, Wolff G, Falck-Pedersen E et al. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 1997;8:37-44.
229. Kass-Eisler A, Falck-Pedersen E, Elfenbein DH et al. The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer. Gene Ther 1994;1:395-402.
230. Lusky M, Grave L, Dieterle A et al. Regulation of adenovirus-mediated transgene expression by the viral E4 gene products: requirement for E4 ORF3. J Virol 1999;73:8308-8319.
231. Gorziglia MI, Lapcevich C, Roy S et al. Generation of an adenovirus vector lacking E1, E2a, E3, and all of E4 except open reading frame 3. J Virol 1999;73:6048-6055.
232. Kass-Eisler A, Leinwand L, Gall J et al. Circumventing the immune response to adenovirus-mediated gene therapy. Gene Ther 1996;3:154-162.
233. Gall J, Kass-Eisler A, Leinwand L et al. Adenovirus type 5 and type 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J Virol 1996;70:2116-2123.
234. Miyazawa N, Leopold PL, Hackett NR et al. Fiber swap between adenovirus subgroups B and C alters intracellular trafficking of adenovirus gene transfer vectors. J Virol 1999;73:6056-6065.
235. Zabner J, Chillon M, Grunst T et al. A chimeric type 2 adenovirus vector with a type 17 fiber enhances gene transfer to human airway epithelia. J Virol 1999;73:8689-8695.
236. Goldman MJ, Wilson JM. Expression of αVβ5 integrin is necessary for efficient adenovirus-mediated gene transfer in human airway. J Virol 1995;69:5951-5958.
237. Douglas JT, Miller CR, Kim M et al. A system for the propagation of adenoviral vectors with genetically modified receptor specificities. Nat Biotechnol 1999;17:470-475.
238. Dmitrev I, Krasnykh V, Miller CR et al. An adenovirus with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998;72:9706-9713.
239. Douglas JT, Rogers BE, Rosenfeld ME et al. Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol 1996;14:1574-1578.
240. Goldman CK, Rogers BE, Douglas JT et al. Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res 1997;57:1447-1451.
241. Rogers BE, Douglas JT, Ahlem C et al. Use of novel crosslinking method to modify adenovirus tropism. Gene Ther 1997;4:1387-1392.
242. Wickham TJ, Lee GM, Titus JA et al. Targeted adenovirus-mediated gene delivery to T cells via CD3. J Virol 1997;71:7663-7669.
243. Bouri K, Feero WG, Myerburg MM et al. Polylysine modification of adenoviral fiber protein enhances muscle cell transduction. Hum Gene Ther 1999;10:1633-1640.
244. Di Nicola M, Milanesi M, Magni M et al. Recombinant adenoviral vector-lipofectAMINE complex for gene transduction into human T lymphocytes. Hum Gene Ther 1999;10:1875-1884.
245. van Belle E, Maillard L, Rivard A et al. Effects of poloxamer 407 on transfection time and percutaneous adenovirus-mediated gene transfer in native and stented vessel. Hum Gene Ther 1998;9:1013-1024.
246. O'Riordan CR, Lachapelle A, Delgado C et al. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther 1999;10:1349-1358.
247. Lieber A, Steinwaerder DS, Carlson CA et al. Integrating adenovirus-adeno-associated virus hybrid vectors devoid of all viral genes. J Virol 1999;73:9314-9324.
248. Zhu J, Grace M, Casale J et al. Characterization of replication-competent adenovirus isolates from large-scale production of a recombinat adenoviral vector. Hum Gene Ther 1999;10:113-121.
249. Blacklow NR, Hoggan MD, Kapikian AZ et al. Epidemiology of adenovirus-associated virus infection in a nursery population. Am J Epidemiol 1968;88:368-378.
250. Berns KI, Pinkerton TC, Thomas GF et al. Detection of adeno-associated virus (AAV)-specific nucleotide sequences in DNA isolated from latently infected Detroit 6 cells. Virology 1975;68:556-560.
251. Lebkowski JS, McNally M, Okarma TB et al. Adeno-associated virus: a vector system for efficient introduction and integration of DNA into a variety of mammalian cells. Mol Cell Biol 1988;8:3988-3996.
252. Cheung AK, Hoggan MD, Hauswirth WW et al. Integration of the adeno-associated virus genome into cellular DNA in latently infected human Detroit 6 cells. J Virol 1980;33:739-748.
253. Buller RM, Janik JE, Sebring ED et al. Herpes simplex virus type 1 and 2 completely help adenovirus-associated virus replication. J Virol 1981;40:241-247.
254. Hoggan MD, Blacklow NR, Rowe WP. Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics. Proc Natl Acad Sci USA 1966;55:1467-1474.
255. Weindler FW, Heilbronn R. A subset of herpes simplex virus replication genes provides helper functions for productive adeno-associated virus replication. J Virol 1991;65:2476-2483.
256. Richardson WD, Westp7hal H. A cascade of adenovirus early functions is required for expression of adeno-associated virus. Cell 1981;27:133-141.
257. Summerford C, Bartlett JS, Samulski RJ. αVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med 1999;5:78-82.
258. Qing K, Mah C, Hansen J et al. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med 1999;5:71-77.
259. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998;72:1438-1445.
260. + hematopoietic progenitor cells: donor variation and correlation of transgene expression with cellular differentiation. J Virol 1997;71:8262-8267.
261. Girod A, Ried M, Wobus C et al. Genetic capsid modifications allow for efficient re-targeting of adeno-associated virus type 2. Nat Med 1999;5:1052-1056.
262. Yang Q, Mamounas M, Yu G et al. Development of novel cell surface CD34-targeted recombinant adenoassociated virus vectors for gene therapy. Hum Gene Ther 1998;9:1929-1937.
263. Bals R, Xiao W, Sang N et al. Transduction of well-differentiated airway epithelium by recombinant adeno-associated virus is limited by vector entry. J Virol 1999;73:6085-6088.
264. Beck SE, Jones LA, Chesnut K et al. Repeated delivery of adeno-associated virus vectors to the rabbit airway. J Virol 1999;73:9446-9455.
265. Summerford C, Samulski RJ. Viral receptors and vector purifications: new approaches for generating clinical-grade reagents. Nat Med 1999;5:587-588.
266. Krieg AM, Yi A-K, Matson S et al. CpG motifs in bacterial DNA trigger direct B cell activation. Nature 1995;374:546-549.
267. Li S, Wu S, Whitmore M et al. Effect of immune response on gene transfer to the lung via systematic administration of cationic lipidic vectors. Am J Physiol 1999;276:796-804.
268. Tan Y, Li S, Pitt BR et al. The inhibitory role of CpG immuno-stimulatory motis in cationic lipid vector-mediated transgene expression in vivo. Hum Gene Ther 1999;10:2153-2161.
269. Ochiya T, Takahama Y, Nagahara S et al. New delivery system for plasmid DNA in vivo using atecollagen as a carrier material: the minipellet. Nat Med 1999;5:707-710.
270. Kollen WJW, Mulberg AE, Wei AE et al. High-efficiency transfer of cystic fibrosis transmembrane conductance regulator cDNA into cystic fibrosis airway cells in culture using lactosylated polylysine as a vector. Hum Gene Ther 1999;10:615-622.
271. Fajac I, Briand P, Monsigny M et al. Sugar-mediated uptake of glycosylated polylysines and gene transfer into normal and cystic fibrosis airway epithelial cells. Hum Gene Ther 1999;10:396-406.
272. Giordano A, Romano G. Gene therapy: where are we going? Clin Ter 1999;150:3-4.